Lydia Usha to Ovarian Neoplasms
This is a "connection" page, showing publications Lydia Usha has written about Ovarian Neoplasms.
Connection Strength
3.495
-
Xenogeneic fibroblasts inhibit the growth of the breast and ovarian cancer cell lines in co-culture. Neoplasma. 2021 Nov; 68(6):1265-1271.
Score: 0.798
-
Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing. J Ovarian Res. 2021 Apr 29; 14(1):61.
Score: 0.770
-
Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion. J Natl Compr Canc Netw. 2020 03; 18(3):223-228.
Score: 0.710
-
Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families? PLoS One. 2018; 13(4):e0195497.
Score: 0.624
-
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study. J Transl Med. 2012 Apr 27; 10:79.
Score: 0.412
-
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol. 2011 Jun 01; 121(3):455-61.
Score: 0.095
-
Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J Clin Oncol. 2020 03 01; 38(7):674-685.
Score: 0.044
-
Olaparib-Induced Severe Folate Deficiency in a Patient With Advanced Ovarian Cancer. J Oncol Pract. 2019 07; 15(7):405-407.
Score: 0.042